SANUWAVE's Call Last Night Said 40–60 Used Units Hit Sales-Can Real Demand Still Save the Stock?

Q2 Revenue Held Up, but New System Sales Were the Weak Link

Sanuwave's latest results look less convincing when you separate top-line revenue from the quality of that revenue. Total revenue was $9.7 million, but only 82 Ultramist systems were sold in Q2, and Q2 2026 revenues were $9.7 million, down 3%. At the same time, management highlighted record sales of consumable applicators, and applicator revenue increased 13%. That creates a clean bull-bear split: consumable demand looks real, but new-equipment demand did not.

Why the mix matters more than the headline number

The quarter was technically above the revised revenue range, but the mix was uglier. Lower system volumes, a higher reseller mix, and roughly 8–9% lower average selling prices compressed margin. Gross margin fell to 76.2% from 78.1%, and GAAP Operating (Loss) Income was $(0.3) million for Q2 2026. That is why the quarter still feels mixed: the consumable tailwind helped, but it did not fully offset weaker hardware demand and lower margins.

The sequence of updates left little time to digest the story

The signal sharpened quickly. Sanuwave first issued a preliminary revenue preview, then the 10-Q was filed yesterday, followed by a live conference call. From there, the next clear repricing point is Q3 2026 earnings, due Friday, August 14.

Used-System Cannibalization Helped Explain the Softness

The call did not resolve the debate on Sanuwave, but it did point investors toward the main pressure area.

What management said about used equipment

Management pointed to the secondary market for used Ultramist systems, and call coverage said the impact was roughly 40–60 used systems that cannibalized new equipment sales. That matters because a used-sale conversion is not the same as fresh new-demand momentum. It can preserve some treatment activity, but it does not deliver the same full upfront equipment economics.

There was also a useful housekeeping note: management said it now checks serial numbers before calling a unit active. That does not change the cleanest demand signal for this quarter, which remains 82 Ultramist systems were sold in Q2.

The product story still has support

The bullish side still has real evidence. In addition to higher applicator revenue, UltraMIST applicator unit volume rose 27% year over year, and the ENERGY FIRST portfolio is designed to accelerate cellular-level wound healing. That suggests the technology still has clinical utility and customers are still using it. The issue is not whether the product works; it is whether near-term demand and margin are strong enough to support the stock.

What the Next Report Needs to Show

SNWV now looks more like a watchlist name than a clear buy until the next data point.

The near-term catalyst window

Investors now have a short window to test whether the second-quarter weakness was temporary or more structural. The next earnings release is due Friday, August 14, and a replay will be available through Friday, August 21, 2026.

What would improve the setup

The next update matters most if it shows progress in three areas:

• New system demand: fewer signs of weaker system sales and a move above the recent 82 Ultramist systems were sold in Q2 read-through.
• Demand quality: less reliance on used equipment and a lower reseller mix.
• Margin resilience: gross margin that holds up after last quarter's 76.2% reading.

If those signals improve, the bull case becomes easier to defend. If not, the evidence still points to a business with genuine consumable demand, but not yet a clean enough hardware recovery.